Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Ascletis Doses First Person in US Trial of Novel NASH Treatment

publication date: Dec 31, 2020

Ascletis of Hangzhou announced its Gannex subsidiary has dosed the first person in a US Phase I trial of ASC42, its NASH treatment. ASC42 is a Farnesoid X Receptor (FXR) agonist. The trial is a randomized, double-blind, placebo-controlled, single and multiple dose escalation study designed to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics (biomarkers - FGF19 and C4) of ASC42 in healthy subjects. Ascletis described the candidate as a novel non-steroidal, selective and potent FXR agonist, with Fast Track designation from the US FDA for NASH. More details....

Stock Symbol: (HK: 1672)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.